¿¬¼ö°­ÁÂ
Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08

Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08
±³À°ÀÏÀÚ : 2023-07-08
±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç

±³À°ÁÖÁ¦ : Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå)

ÁÖÃÖ±â°ü : »ï¼º¼­¿ïº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú

´ã´çÀÚ : ¹Ú¹Ì³ª
¿¬¶ôó : 02-3410-3569

À̸ÞÀÏ : minasun.park@samsung.com

±³À°Á¾·ù : ÀÇ»çÇÐ

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 08:55~09:00 °³È¸»ç ÇÔµ·ÀÏ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:00~09:10 Anatomy in glaucoma ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:10~09:20 Molecular biology in glaucoma Á¶Çö°æ(°æ»óÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:20~09:30 Pathophysiology in glaucoma ±è¿µ±¹(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:30~09:40 Animal models in glaucoma ³ë½Â¼ö(Â÷ÀÇ°úÇдë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:40~09:50 Lymphatics and glaucoma ¹Úµµ¿µ(¼º±Õ°üÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:50~10:10 Discussion ( )

ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:10~10:25 Coffee Break ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:25~10:35 Myopia: How does it affect glaucoma? ±è¸¶¸£´Ù(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:35~10:45 Optic disc morphology: Does It predict the future VF defect pattern? ÇÑÁ¾Ã¶(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:45~10:55 FDT & 10-2 VF: Do they offer additional information? Á¤°æÀÎ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:55~11:05 AngioOCT: The tips how to use AngioOCT in glaucoma clinic ¼­¹ÎÈñ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:05~11:15 ICP: The influence of CSF pressure in glaucoma ±è°íÀº(¿ï»êÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:15~11:35 Discussion ( )

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:35~12:05 Special Session :³ì³»Àå°ú ÇÔ²²ÇÑ 30¿©³â ±ââ¿ø(¼º±Õ°üÀÇ´ë)

½Ä»ç 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ǪµåÄÚÆ® 12:05~13:30 LUNCH ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:30~13:40 Congenital glaucoma ¼­¿ï(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:40~13:50 Traumatic glaucoma ÀÌ°æ¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:50~14:00 Uveitic glaucoma ÃÖÁø¾Æ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:00~14:10 Pseudoexfoliative glaucoma ±èÁ¤¸²(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:10~14:20 Neovascular glaucoma ÀÌÁö¿õ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:20~14:30 Malignant glaucoma ÀÌÅÂÀº(ÀüºÏÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:30~14:50 Discussion ( )

ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:50~15:05 Coffee Break ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:05~15:20 How to interpret the measured IOP in clinic when we consider the diurnal variation of IOP À¯Á¤±Ç(°í·ÁÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:20~15:35 How to determine the progression when we meet glaucoma patients with VF progression but without ONH change. ¹èÇü¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:35~15:50 Targeting IOP: What should we do when we meet persistent progression of glaucoma patients with low teen IOP? ÀÌÀºÁö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:50~16:05 Why are there many NTG patients in Asian population? Á¤Áø¿í(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:05~16:20 Strategies for neuroprotection: Which should be the main target – ganglion cell, axon, or glial cell? ¹ÚÇý¿µ(°¡Å縯ÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:20~16:50 Discussion ( )

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:50~16:55 Æóȸ»ç ( )

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 3,088 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,969 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù) : 2024-04-20

±³À°ÀÏÀÚ : 2024-04-20 ±³À°Àå¼Ò : ¿Â¶óÀÎ (24½Ã°£ VOD ´çÀÏ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,855 , ´ñ±Û¼ö : 1

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,718 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-17

±³À°ÀÏÀÚ : 2024-04-17 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã´çÀÚ : °­ÈÆ ¿¬¶ôó

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,891 , ´ñ±Û¼ö : 0